title: No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects.
abstract: OBJECTIVE
  The endocannabinoid system can exert beneficial effects on gastrointestinal inflammation, and cannabinoid receptor-2 (CB2) agonists may represent a new therapeutic approach in inflammatory bowel disease (IBD). A functional CB2 Q63R polymorphism (rs35761398) in the CNR2 gene has been shown to affect the immunomodulating properties of the CB2 receptor. We sought to investigate whether the functional CB2 Q63R polymorphism (rs35761398) is associated with IBD susceptibility in a Turkish clinical sample.
  
  
  METHODS
  A total of 202 IBD patients, comprising 101 Crohn's disease (CD) patients and 101 ulcerative colitis (UC) patients, and 101 healthy controls were included in the study. The CB2 Q63R polymorphism was genotyped using real-time PCR.
  
  
  RESULTS
  There were no significant differences in the genotype frequencies of the three study groups. The odds ratio of the minor Q allele for CD relative to the common R allele was not significant (OR =1.02, 95% CI =0.67-1.56, p=0.99). Similarly, the odds ratio of the minor Q allele for UC relative to the common R allele did not reach statistical significance (OR =1.10, 95% CI =0.72-1.68, p=0.75). Moreover, the genotype frequencies did not show any significant association with the disease extent in either CD (p= 0.71) or UC patients (p=0.59).
  
  
  CONCLUSIONS
  These pilot findings suggest that CB2 Q63R polymorphism does not play a major role in genetic susceptibility to IBD or in its disease phenotypes among Turkish subjects.
authors.affiliation: Department of Gastroenterology, Marmara University Faculty of Medicine, İstanbul, Turkey. oya_yonal@yahoo.com.
authors.forename: Oya
authors.initials: O
authors.lastname: Yonal
authors.forename: Fatih
authors.initials: F
authors.lastname: Eren
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yılmaz
authors.forename: Özlen
authors.initials: Ö
authors.lastname: Atuğ
authors.forename: Hülya Hamzaoğlu
authors.initials: HH
authors.lastname: Över
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D043885:Receptor, Cannabinoid, CB2 / Q000235:genetics*; D014421:Turkey
chemical_list: C588309:CNR2 protein, human; D043885:Receptor, Cannabinoid, CB2